Oncogenesis is tightly connected with dysregulated gene expression. Alterations occur at many levels, including in posttranscriptional regulatory elements that control the stability, cellular localisation or translation efficiency of messenger ribonucleic acids (mRNAs). These elements are located primarily in the 3′ untranslated region (UTR) of mRNAs. Multiple examples are known of oncogenes whose activity and function become altered owing to changes in their 3′ UTRs. Strikingly, recent studies have uncovered global changes of 3′ UTRs in cancers, going beyond individual genes. Cancer cells express transcripts with systematically shorter 3′ UTRs compared to normal cells. The implications of these changes for cellular biology are poorly understood, but high‐throughput approaches are being developed to uncover the regulators, targets and impact of 3′ UTR‐based regulation. The hope is that a renewed understanding of 3′ UTR alterations can open new therapeutic opportunities.
Key Concepts
The maturation of most messenger RNAs includes 3′ end cleavage followed by the addition of a polyadenosine tail.
Most human protein‐coding genes express multiple isoforms, which can differ, among others, in their 3′ untranslated regions (3′ UTRs).
In proliferating cells, including cancer cells, cleavage and polyadenylation tend to occur at coding region proximal sites, giving rise to isoforms with short 3′ UTRs.
As 3′ UTRs contain binding sites for many RNA‐binding regulatory proteins, it is likely that short 3′ UTR isoforms are less susceptible to posttranscriptional regulation.
A role of 3′ UTR length changes in the progression and prognosis of cancers has been proposed.